David R. Bauer
Lawyers
Filters
Davis Polk Advises Roche on Its Acquisition of Foundation Medicine
Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by Roche at a price of $137.00 per share in cash. The transaction is…
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offering of Common Stock
Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock, which included the full exercise of the underwriters’ option to…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…
Iterum Therapeutics plc Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…
Calyxt, Inc. Common Stock Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 4,057,500 shares of common stock of Calyxt, Inc., including 457,500…
Cellectis S.A. Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis S.A. of 5,646,000 American Depositary Shares, each representing…
Dova Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $80 million public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on the NASDAQ…
Avadel Pharmaceuticals $143.7 Million Exchangeable Senior Notes Offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Avadel Finance Cayman Limited, a wholly owned subsidiary of Avadel Pharmaceuticals plc, of $143.7 million aggregate…
Davis Polk Advises Roche on Its Acquisition of Flatiron Health
Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…
Solid Biosciences Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…